Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05515029 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Calcineurin Inhibitor at Patients With Hemoblastosis

StatusActive, Not Recruiting
PhasePhase 3
Started2022-08-23
View on ClinicalTrials.gov ↗
Record status
This record was last updated September 28, 2023 (before its estimated August 15, 2024 completion). Its status may not reflect the trial's current state.

Amendment history

2023-09-26
Recruiting→Active, Not Recruiting Study Status, Study Design, Contacts/Locations v2
Trial statusRecruiting→Active, Not Recruiting
Primary completion date2025-08-15→2024-08-15
Enrollment targetestimated 50→confirmed 56
Study sitesdetails revised at 1 of 1 site
2023-03-27
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Study sites0→1
2022-08-23
Original filing
GVHD prevention using a combination of post-transplantation cyclophosphamide in combination with abatacept, vedolizumab and calcineurin inhibitor in children and young adults with hematoloblastosis after myeloablative conditioning regimen with treosulfan/TBI, cyclophosphamide/etoposide, fludarabine after HSCT from matched unrelated and haploidentical donors
Trial Details
NCT Number NCT05515029
Lead Sponsor Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Conditions Acute Lymphoblastic Leukemia, Myeloblastic Leukemia, Biphenotypic Acute Leukemia, Malignant Lymphoma, Myelodysplastic Syndromes, Juvenile Myelomonocytic Leukemia
Enrollment 56 participants
Start Date 2022-08-23
Primary Completion 2024-08-15 (estimated)
Study Completion 2026-10-16 (estimated)
Updated on ClinicalTrials.gov 2023-09-28